We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | 0.40 | 0.55 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
16/1/2019 17:24 | Down 6%, top up ? | mike1608 | |
16/1/2019 12:55 | a week old but may be of interest to anyone who missed it... FDA decision on Iclaprim expected February 13? | bountyhunter | |
16/1/2019 08:20 | Looks like it tried to backtest 36p but support kicked in well before that level - missed the action yesterday but may get a chance to buy a dip today | return_of_the_apeman | |
15/1/2019 17:58 | No delay here as pointed out clearly yesterday. Good day today, nice shake out ditching plenty traders/chancers followed by a good recovery back over 40p to finish with a touch of red to cool techs. 20 trading days left to Fda D day. Exciting times ahead. | ianb5004 | |
15/1/2019 15:21 | positive write up on sh-areprophets | andrbea | |
15/1/2019 13:51 | This will probably end up blue today. | timberwolf3 | |
15/1/2019 13:06 | No just the ATs kicking in. | l4z4rus | |
15/1/2019 12:53 | I assume the fall is now something to do with FDA shutdown. Everything's getting delayed. | waterloo01 | |
15/1/2019 12:27 | Buy for the medium-long term imo nai dyor | bountyhunter | |
15/1/2019 12:16 | Hold or sell? | mike1608 | |
15/1/2019 10:19 | This one had a phenomenal run from 25 to 40p, a 60% rise. I expect a correction now to the mid 30s. Also, during the new year many would have bought this for extended settlements which would now be due for settlement. This could cause further pressure on the share price. | infoanish | |
15/1/2019 07:37 | Sorry - I mean FDA running out of cash! Seems around March... | 123js | |
15/1/2019 07:30 | 123JS AS long as they don't try to fund any novel developments themselves cash should be ample - hence the likelihood is going to be a partnership - announced very soon the proce action suggests. Where do you see the problem and to exactly (££&poun | small crow | |
15/1/2019 06:45 | Can't quite see it so equivocally - but that article is more reassuring than what I could find...the wrinkle of fee waiver adds a question in my mind. Timing seems to be a little tight before the money runs out...on balance though fair to think it shouldn't be impacted... | 123js | |
14/1/2019 22:34 | Well at least one bluey on this thread is clearly hoping to get in lower! Expect a bit of deramping tomorrow. | bountyhunter | |
14/1/2019 20:59 | Topped up today. If approved as a new antibiotic Iclaprim will be of huge significant globally especially with resistance to existence antibiotics increasing all the time. | bountyhunter | |
14/1/2019 20:56 | hxxps://www.stitcher Good listen 10.45 in | ianb5004 | |
14/1/2019 20:55 | hxxps://www.statnews As you can see this will NOT effect the Approval decision for Iclaprim only new NDA submissions. | ianb5004 | |
14/1/2019 17:02 | The relevant piece in the article seems to be:- "While the FDA is continuing to carry out reviews funded by fiscal year (FY) 2018 Prescription Drug User Fee Act user fees, including the review and approval of new drugs and biologics funded by carryover user fee balances, the agency is not accepting FY 2019 user fees until funding appropriations have been authorized, i.e., the political impasse has been resolved. Consequently, the FDA has suspended reviews of existing Investigational New Drug (IND) and Biologics License Application (BLA) applications not covered by user fees, and is not reviewing applications for new drugs and biologics submitted during the shutdown period, except for emergency INDs and BLAs." As Motif Bio's review began in August 2018, surely that shouldn't be affected? | alan@bj | |
14/1/2019 13:45 | Could be.www.forbes.com/si | richard xii | |
14/1/2019 13:24 | Does government shutdown impact timing here? Activities funded by fees continue - ie new drug review and approvals - but if that fee is waived does that complicate? | 123js | |
11/1/2019 16:42 | Nice run of trades in the last hour and rise into the close bodes well for Monday | return_of_the_apeman | |
11/1/2019 14:43 | Thanks return_of_the_apeman | richard xii |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions